Dr. Reddy’s Laboratories Ltd (NYSE:RDY) Stock Has Average Price Target of $492.90 According to Brokerages

Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Get Free Report) have been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $492.90.

A number of analysts have recently issued reports on RDY shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 21st. Citigroup raised shares of Dr. Reddy’s Laboratories from a “sell” rating to a “buy” rating and upped their price target for the stock from $1,040.00 to $1,450.00 in a research note on Tuesday, September 29th. JPMorgan Chase & Co. upgraded shares of Dr. Reddy’s Laboratories from an “underweight” rating to a “neutral” rating in a report on Monday, October 26th. Wall Street Zen upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, October 17th. Finally, Jefferies Financial Group raised shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “hold” rating and set a $13.90 price target on the stock in a research report on Sunday, October 25th.

Read Our Latest Stock Analysis on RDY

Dr. Reddy’s Laboratories Stock Up 0.4%

Dr. Reddy’s Laboratories stock opened at $14.89 on Thursday. The stock has a fifty day simple moving average of $13.34 and a two-hundred day simple moving average of $13.32. The firm has a market cap of $12.43 billion, a price-to-earnings ratio of 40.23, a PEG ratio of 3.08 and a beta of 0.31. The company has a current ratio of 1.93, a quick ratio of 1.40 and a debt-to-equity ratio of 0.03. Dr. Reddy’s Laboratories has a 12 month low of $11.36 and a 12 month high of $15.67.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last issued its earnings results on Saturday, October 24th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. The firm had revenue of $903.89 million during the quarter, compared to analyst estimates of $894.94 million. Dr. Reddy’s Laboratories had a net margin of 8.56% and a return on equity of 7.91%. Equities analysts predict that Dr. Reddy’s Laboratories will post 0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in RDY. American Century Companies Inc. raised its stake in shares of Dr. Reddy’s Laboratories by 5.1% in the third quarter. American Century Companies Inc. now owns 1,924,849 shares of the company’s stock worth $24,292,000 after purchasing an additional 93,966 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth $80,000. Allworth Financial LP lifted its holdings in shares of Dr. Reddy’s Laboratories by 37.0% in the third quarter. Allworth Financial LP now owns 11,043 shares of the company’s stock worth $139,000 after buying an additional 2,981 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Dr. Reddy’s Laboratories by 54.8% in the third quarter. Goldman Sachs Group Inc. now owns 1,630,395 shares of the company’s stock worth $20,576,000 after buying an additional 576,908 shares in the last quarter. Finally, Jump Financial LLC lifted its position in Dr. Reddy’s Laboratories by 273.3% during the third quarter. Jump Financial LLC now owns 389,000 shares of the company’s stock valued at $4,909,000 after purchasing an additional 284,800 shares during the last quarter. Institutional investors own 3.85% of the company’s stock.

About Dr. Reddy’s Laboratories

(Get Free Report)

Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.

Featured Articles

Analyst Recommendations for Dr. Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.